Kranzler H R, Del Boca F, Korner P, Brown J
Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT 06030-2103.
J Subst Abuse Treat. 1993 May-Jun;10(3):283-7. doi: 10.1016/0740-5472(93)90076-e.
Open-label and placebo-controlled trials of fluvoxamine, a selective, serotonergic antidepressant, were conducted as an adjunct to relapse prevention psychotherapy in alcoholics. In the open trial, 16 inpatient alcoholics began a 12-week treatment program, with 10 patients dropping out during the first 4 weeks of treatment. In the controlled trial, 8 of 10 patients on fluvoxamine dropped out during the first 4 weeks of treatment, compared with only 1 of 9 patients on placebo. Baseline patient characteristics did not appear to explain the differential attrition in the controlled trial, although the placebo-treated patients were more alcohol dependent. In both trials, patients on fluvoxamine complained of a variety of adverse effects, which they often identified as the basis for early termination of treatment. These adverse effects appear to limit the usefulness of the medication for the treatment of alcoholism.
对选择性5-羟色胺能抗抑郁药氟伏沙明进行了开放标签试验和安慰剂对照试验，该试验作为酗酒者预防复发心理治疗的辅助手段。在开放试验中，16名住院酗酒者开始了一个为期12周的治疗项目，其中10名患者在治疗的前4周内退出。在对照试验中，服用氟伏沙明的10名患者中有8名在治疗的前4周内退出，而服用安慰剂的9名患者中只有1名退出。尽管接受安慰剂治疗的患者酒精依赖程度更高，但基线患者特征似乎无法解释对照试验中的差异损耗。在两项试验中，服用氟伏沙明的患者都抱怨有各种不良反应，他们常常将这些不良反应视为提前终止治疗的依据。这些不良反应似乎限制了该药物在治疗酗酒方面的效用。
